Scpharmaceuticals (NASDAQ:SCPH) Now Covered by Analysts at HC Wainwright

Analysts at HC Wainwright started coverage on shares of Scpharmaceuticals (NASDAQ:SCPH) in a research note issued to investors on Tuesday, Marketbeat reports. The brokerage set a “buy” rating and a $13.00 price target on the stock. HC Wainwright’s price objective would indicate a potential upside of 109.34% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Zacks Investment Research lowered Scpharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, October 9th. ValuEngine lowered Scpharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 6th. Four equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $8.00.

Scpharmaceuticals stock opened at $6.21 on Tuesday. Scpharmaceuticals has a 52 week low of $2.44 and a 52 week high of $7.85. The business has a 50-day simple moving average of $6.24 and a 200 day simple moving average of $4.54. The company has a quick ratio of 6.04, a current ratio of 6.04 and a debt-to-equity ratio of 0.10. The stock has a market cap of $109.63 million, a price-to-earnings ratio of -3.91 and a beta of 0.82.

Scpharmaceuticals (NASDAQ:SCPH) last posted its earnings results on Wednesday, August 7th. The company reported ($0.39) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.49) by $0.10. On average, research analysts anticipate that Scpharmaceuticals will post -1.86 earnings per share for the current year.

A number of hedge funds have recently modified their holdings of SCPH. Eversept Partners LP bought a new stake in Scpharmaceuticals during the second quarter worth about $556,000. Alambic Investment Management L.P. bought a new stake in Scpharmaceuticals during the second quarter worth about $191,000. Paloma Partners Management Co bought a new stake in Scpharmaceuticals during the second quarter worth about $96,000. Jacobs Levy Equity Management Inc. lifted its stake in Scpharmaceuticals by 55.8% during the second quarter. Jacobs Levy Equity Management Inc. now owns 36,921 shares of the company’s stock worth $118,000 after purchasing an additional 13,225 shares during the last quarter. Finally, Morgan Stanley lifted its stake in Scpharmaceuticals by 32.0% during the second quarter. Morgan Stanley now owns 13,633 shares of the company’s stock worth $43,000 after purchasing an additional 3,306 shares during the last quarter. 39.67% of the stock is owned by hedge funds and other institutional investors.

Scpharmaceuticals Company Profile

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is Furoscix that consists of proprietary subcutaneous formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients outside of the acute care setting.

Read More: Average Daily Trade Volume Explained

Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.